Navigation Links
Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
Date:5/21/2008

BERKELEY HEIGHTS, N.J., May 21 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced that multiple abstracts featuring its lead oncology products will be featured at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 30 - June 3, 2008.

The abstracts include the following:

-- Initial Phase 1 Clinical and Pharmacokinetic Assessment of G4544, an

oral gallium-containing Compound. Poster # 53C Abstract No: 8592

Saturday, May 31, 2008.

-- A Phase I/II Study to Determine the Feasibility and Efficacy of the

Triple Combination of Oblimersen (OBL), Abraxane (ABX), and

Temozolomide (TMZ) in Metastatic Melanoma and Normal LDH. Poster # 16

Abstract No: 9027 Sunday, June 1, 2008.

-- Effect of the Addition of Oblimersen (Bcl-2 antisense) to

Fludarabine/Cyclophosphamide for Relapsed/Refractory Chronic

Lymphocytic Leukemia (CLL) on Survival in Patients Who Achieve CR/nPR:

Five-year Follow-up from a Randomized Phase III Study. Abstract # 7008

Monday, June 2, 2008.

-- Prognostic Impact of Baseline LDH on Survival Independent of Tumor

Burden in Advanced Melanoma: Results of Phase III Trial of

Oblimersen-Dacarbazine (OBL-DTIC) vs. DTIC. (Publication).

-- Short IV Infusion of Oblimersen (OBL) in Patients with Solid Tumors:

Safety and Pharmacokinetics. (Publication).

-- Pharmacokinetics of Albumin-bound Paclitaxel (ABX) in combination with

Temozolomide (TMZ) and Oblimersen Sodium (OBL) in Patients with

Advanced Melanoma. (Publication).

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medici
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
3. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
4. Genta Incorporated Announces Third Quarter 2007 Financial Results
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Clinical Programs Featured at American Society of Hematology Meeting
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
10. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
11. Genta Receives Key Patent Related to Oral Gallium Compound G4544
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015 PharmaPoint: Type 1 Diabetes ... Summary Type 1 diabetes (T1D) is an autoimmune disease ... means that the body can no longer produce insulin. Over ... as at present, no other treatment can be offered to ... of insulin analogs with different times of action - long-acting ...
(Date:5/27/2015)... 27, 2015  Precision Advisors ( www.precisionadvisors.com ), a ... 2015 Digital Trends Study of 145 managed care executives. ... the concepts of big data and predictive analytics, but ... The Health Information Technology for Economic and Clinical ... make use of electronic medical records (EMRs) by 2014. ...
(Date:5/27/2015)... -- LumiThera Inc., a developmental stage medical device company ... disorders and disease, announced today that they were ... Life Sciences Discovery Fund (LSDF) commercialization grant. LumiThera was ... grants worth $500,000 to provide for commercialization activities ... macular degeneration (AMD). LSDF executive ...
Breaking Medicine Technology:PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 4Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 2Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 3LumiThera Receives LSDF Commercialization Grant Award 2
... TUSTIN, Calif., Dec. 5, 2011  Radient Pharmaceuticals Corporation ... In Vitro Diagnostic (IVD) cancer test, ... to the 2012 Gastrointestinal Cancers Symposium (ASCO Conference) ... submitted. The meeting will be held on January ...
... ANGELES, December 2, 2011  WestPark Capital, Inc. announced the ... Amex: ISR). A total of 2,817,988 shares of common stock ... common stock were sold, generating gross proceeds of $2,592,549 ... to fund new applications for IsoRay,s Cesium-131 technology to ...
Cached Medicine Technology:Radient Pharmaceuticals' Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presentation 2Radient Pharmaceuticals' Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presentation 3WestPark Capital, Inc. Announces $2.6 Million IsoRay Offering 2
(Date:5/28/2015)... 28, 2015 Orem, UT—Dymicron, Inc., (dymicron.com) ... using their unique Triadyme-C cervical total disc replacement device. ... William D. Smith at the American Institute of Minimally ... are responding well to the implantation of the Dymicron ... Spine Center and Chief of Neurosurgery for the University ...
(Date:5/28/2015)... Omaha, NE (PRWEB) May 28, 2015 ... healthcare staffing, including nurse practitioner jobs, has announced that ... Association of Nurse Practitioners’ 2015 National Conference to be ... , AANP offers educational programming, networking opportunities, and ... Aureus Medical’s Advanced Practice division will be ...
(Date:5/28/2015)... 2015 Peggy J. Lynam, PT, DPT, NCS ... American Physical Therapy Association House of Delegates for the New ... Delegate Assembly. This will be her second term. ... coordinator and principle spokesperson for the Chapter delegation and presides ... or Delegate Assembly may direct the Chief Delegate to present ...
(Date:5/27/2015)... Gravity and volume loss in the skin have ... Holly CaSaroll, is excited to introduce a custom menu ... face, without surgical intervention, and without downtime. , “We ... approved procedure that can lift skin using focused ultrasound, ... new more lifting formula than its predecessor Radiesse, to ...
(Date:5/27/2015)... Thermage was the first to come out with ... 2007 coinciding with the release of NXT or CPT, the ... Aesthetics was the first practice in New York to debut ... results that had never been achieved before non-surgically. Even ... considered by many as the leading skin tightening device. ...
Breaking Medicine News(10 mins):Health News:Dymicron, Inc., Announces the First Human Implantation of their Triadyme-CTM Cervical Total Disc Replacement Device in Cyprus 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the American Association of Nurse Practitioners’ 2015 National Conference 2Health News:Skin Expert Holly CaSaroll Announces New Cutting Edge Results with RadiessePlus Filler Available at Detroit Skin and Wellness Clinic 2Health News:Non-Surgical Fat Reduction and Skin Tightening Procedures, Thermage and Exilis, Increase 200% at Precision Aesthetics in New York, April 2015 2
... hospital ranked as one of Americas Best by U.S. News ... days than those admitted to a non-ranked hospital , according ... of Internal Medicine, one of the JAMA/Archives journals. ... mortality measures that are publicly reported by the Centers for ...
... eating uncooked fish dishes like koi-pla puts people in ... cause a type of liver cancer called cholangiocarcinoma ... weeks PLoS Medicine. ,Banchob Sripa (Khon Kaen ... food-borne trematode Opisthorchis viverrini (the SE Asian liver fluke) ...
... research, published in the July issue of the journal ... method for enhancing the potency and effectiveness of ... a variety of human cancers. , A ... human cancer cells to a promising treatment currently being ...
... According to a study published in the July 10, ... American Academy of Neurology , People with early Parkinsons ... of hallucinations, sleepiness, and swelling. ,By identifying ... for early intervention and possibly reduce disability, said study ...
... fashion designer Giorgio Armani's group said Wednesday it will open ... of both hot springs and high fashion. ... Ginza, one of Tokyo's ritziest districts, as part of its ... market. ,The 6,000 square-meter (65,000 square-foot) complex opening ...
... of British scientists claims they can soon release the worlds ... so, the NHS Trust of UK will stand to save billions ... most common neurological diseases in the western world, costs the NHS ... scientists, they have identified a series of proteins, which are most ...
Cached Medicine News:Health News:Americas Best Hospital Reduced Heart Attack Rates 2Health News:Americas Best Hospital Reduced Heart Attack Rates 3Health News:New Cancer Therapy in Clinical Trial 2Health News:Early Parkinsons Show Hallucination,sleepiness 2Health News:Simple Blood Test May Predict Alzheimers Disease 2
... Ultra thin collagen coated highly ... ultra thin wall construction offers ... The Hemacarotid UltraThin Patch provides ... conformability, and healing, without suture ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery...
... EVS is engineered to close arteriotomies ... ergonomic stapler with a simple trigger ... A deliver sheath gently locks ... control of the site before, during, ...
Medicine Products: